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THOMAS R. HOWDIESHELL,1 DAITHI HEFFERNAN,1 and JOSEPH T. DIPIRO2
For the Therapeutic Agents Committee of the Surgical Infection Society
ABSTRACT
Background: Recommendations for vaccination of injured patients against infection are evolv-
ing. Newly-recognized infections, safety considerations, changing epidemiology, and redefi-
nition of patient groups at risk are factors that may influence vaccine development priorities
and recommendations for immunization. However, recommendations must often be formu-
lated based on incomplete data, forcing reliance on expert opinion to address some crucial
questions. These guidelines provide evidence-based recommendations for the prevention or
treatment of infectious morbidity and mortality after traumatic injury, such as soft tissue
wounds, human or animal bites, or after splenectomy.
Methods: A panel of experts conducted a thorough review of published literature, as well
as information posted on the internet at the websites of the U.S. Centers for Disease Control
and Prevention, among others. MEDLINE was searched for the period 1966–2004 using rele-
vant terms including “anthrax,” “rabies,” “tetanus,” “tetanus toxoid,” and “ splenectomy,” in
combination with “vaccine” and “immunization.” The Cochrane database was searched 
also. Reference lists were cross-referenced for additional relevant citations. All published re-
ports were analyzed for quality and graded, with the strength of the recommendation pro-
portionate to the quality of the supporting evidence.
Results: Recommendations are provided for pre- and post-exposure prophylaxis of rabies
and anthrax. For tetanus prophylaxis, recommendations are provided for prophylaxis of acute
wounds stratified y age and prior immunization status, and for immunization of persons at
high risk. After splenectomy, it is recommended that all persons ages 2–64 years receive 23-
valent pneumococcal vaccine and meningococcal vaccine, with Haemophilus influenzae type
B vaccine administered to high-risk patients as well (all are Grade D recommendations). Vac-
cination should be given two weeks before elective splenectomy (Grade C), or two weeks af-
ter emergency splenectomy (Grade D). A booster dose of pneumococcal vaccine is recom-
mended after five years (Grade D); no re- vaccination recommendation is made for
meningococcal or Haemophilus influenzae type B vaccine.  Recommendations for prophy-
laxis of splenectomized children under the age of five years are also provided.
Conclusion: There are limited data on the use of vaccines after injury.  This document brings
together a disparate literature of variable quality into a discussion of the infectious risks af-
ter injury relevant to vaccine administration, a summary of safety and adverse effects of vac-
cines, and evidence-based recommendations for vaccination.
1Department of Surgery, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
2South Carolina College of Pharmacy, Charleston, South Carolina.
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IN THE 21ST CENTURY, nearly any antigen can beprepared for use as a vaccine. The difficulties
are in identifying protective antigens and per-
suading the immune system to respond correctly
to them. Over the last 200 years, success has been
achieved in controlling major infectious diseases
predominantly by vaccinating with attenuated
living or inactivated organisms, inactivated tox-
oids, or bacterial capsular polysaccharides. Vac-
cine preparation with attenuated or killed or-
ganisms has not required extensive knowledge
of immune responses, except to be sure that an-
tibodies are produced. Control of bacteremia or
viremia has sufficed to provide efficacy against
many of the diseases controlled by vaccination
[1]. Now, more complex problems must be dealt
with, such as microbes that are not inhibited by
antibodies and immune responses that are use-
less or even pathologic.
In recent years, a better understanding of
protective immune responses has included
recognition of the need to induce both specific
cellular immune responses and antibodies to
control infections. Antibodies on mucosal sur-
faces and in serum can prevent infection or
limit spread to target organs, whereas T-cell
Th1 and Th2 responses that shift the immune
system toward cellular or antibody-mediated
immunity, respectively, destroy infected cells
and eliminate infection [1].
Recommendations for immunizations are
evolving. Newly recognized infections, safety
considerations, changing epidemiology, and
the identification of new risk groups are im-
portant factors that may influence vaccine de-
velopment priorities and immunization rec-
ommendations. In addition, dramatic advances
in molecular biology have made possible the
development of many new and future vaccines
and combination products.
Development of vaccine policy is difficult
and complex work, tempered by judgment and
elements of uncertainty [1]. The recommenda-
tions made by the Advisory Committee on Im-
munization Practices (ACIP) of the U.S. Cen-
ters for Disease Control and Prevention (CDC),
the Committee on Infectious Disease of the
American Academy of Pediatrics, and other au-
thorities are not without controversy. Recom-
mendations often must be formulated on the
basis of incomplete data, necessitating vigor-
ous debate to achieve consensus.
The purpose of this document is to provide
evidence-based recommendations on the use of
vaccines for the prevention or treatment of in-
fectious morbidity and mortality after trau-
matic injury. Injuries necessitating immuniza-
tion include trauma necessitating splenectomy,
human or animal bites, and other soft tissue
wounds. In addition, the threat of biologic
agent attacks has added the potential for in-
fection with microorganisms such as anthrax.
There are limited data on the current use of
vaccines after injury. Although recommenda-
tions for the use of rabies and tetanus vaccines
exist, their utility after injury is poorly docu-
mented [2,3]. A 2002 survey of 557 trauma sur-
geons documented a lack of consensus regard-
ing the immunization of post-splenectomy
patients [4].
This document presents a focused review of
the infectious risk after injury, evidence sup-
porting the use of vaccines in these circum-
stances, a summary of safety and adverse effects
of vaccines, and evidence-based recommenda-
tions for vaccination after injuries that carry a
risk of rabies or tetanus and after splenectomy.
In addition, a recommendation is provided for
use of anthrax vaccine.
METHODS
The recommendations were developed by an
expert panel, who conducted a thorough re-
view of the published literature as well as the
information available on federal government
internet sites such as that of the CDC
(www.cdc.gov). The MEDLINE database was
searched using multiple strategies to identify
clinical trials of efficacy and reports of adverse
events published from 1966 to 2004, and this
was supplemented by manual search of refer-
ences from all relevant journal articles. The
terms used for these searches included “an-
thrax,” “rabies,” “tetanus,” “tetanus toxoid,”
and “splenectomy,” in combination with the
terms “vaccine” and “immunization.” In addi-
tion, the Cochrane database was searched for
any relevant documents.
All published reports were categorized by
quality, and each trial was graded according to
the method described in Table 1 [5]. Large ran-
domized trials with clear-cut results were given
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TABLE 1. RECOMMENDATIONS AND EVIDENCE
GRADING SYSTEM
Grading of recommendations
A. Supported by at least two level I investigations
B. Supported by one level I investigation
C. Supported by level II investigations only
D. Supported by at least one level III investigation
E. Supported by level IV or V evidence
Grading of evidence
I. Large randomized trials with clear-cut results;
low risk of false-positive (alpha) error or false-
negative (beta) error
II. Small randomized trials with uncertain results;
moderate to high risk of false-positive (alpha)
and/or false-negative (beta) error
III. Nonrandomized, contemporaneous controls
IV. Nonrandomized, historical controls and expert
opinion
V. Case series, uncontrolled studies, and expert
opinion
Adapted from Sackett [5].
the greatest weight, followed by small ran-
domized trials and then by non-randomized
studies. The lowest quality of evidence in-
cluded case studies, uncontrolled studies, and
expert opinion. A recommendation grade of A,
B, or C had to be supported by randomized tri-
als. An executive summary of the graded rec-
ommendations is presented in Table 2.
The document has been reviewed and en-
dorsed by the Therapeutic Agents Committee
and the Executive Council of the Surgical In-
fection Society.
RESULTS
Rabies
Risk of rabies after injury. Rabies is a viral in-
fection transmitted in the saliva of infected an-
imals. The infection is widespread in some an-
imal species, and occasionally is transmitted to
human beings. Over the last 50 years, the inci-
dence of rabies has declined significantly in the
industrialized world, although developing na-
tions still have a high case rate. The geographic
distribution of human cases generally follows
the distribution of animal cases, but persons re-
turning from endemic areas may import the
disease to non-endemic areas [6].
Although human rabies infection is rare in
the U.S., animal bites are encountered fre-
quently in clinical practice, as several million
U.S. residents are victims each year. Dog bites
alone account for more than 300,000 emergency
department visits annually, with total costs of
more than $100 million [7].
Rabies is invariably fatal in the absence of
specialized treatment, but is preventable with
proper measures, including prophylaxis after
certain types of animal exposure. Control of ra-
bies in domestic animal populations and post-
exposure prophylaxis has led to a decline in an-
nual human rabies cases in the U.S. from more
than 100 at the beginning of the 20th Century
to 1 to 3 per year. Only 32 cases of human 
rabies were diagnosed in the U.S. between 1980
and 1998 [6].
Since the 1970s, the expanding epizootic of
rabies in raccoons in the eastern U.S. has in-
creased concern about potential transmission
to man. In 1997, 8,509 animal rabies cases were
reported in the U.S., an increase of 19.4% from
1996 [8]. Rabies appears to be expanding in rac-
coons, and reports of rabies in cats have in-
creased in the same areas. Although no docu-
mented human infections have occurred with
the raccoon rabies virus variant, the use of ra-
bies post-exposure prophylaxis has increased
recently [9]. In 1987, approximately 18,000 ra-
bies post-exposure prophylaxis treatments
were given in the U.S., whereas in 1997, an es-
timated 39,000 treatments were given. Al-
though the costs of rabies post-exposure pro-
phylaxis can vary greatly, the cost in the U.S.
is approximately $1,500 per course for bio-
logics alone. Physician and follow-up clinic
charges add to the cost [10].
Pathogenesis. Rabies is an acute progressive
encephalitis caused by RNA viruses in the fam-
ily Rhabdoviridae, genus Lyssavirus [11]. Rabies
virus is the only known lyssavirus in the New
World. Some locations are considered rabies-
free; among them are Hawaii and many Pacific
and Caribbean islands (except Cuba, Dominican
Republic, Haiti, Grenada, and Puerto Rico).
However, their continued freedom from rabies
depends on prevention of the introduction of
the virus and laboratory-based surveillance [12].
The rabies virus is highly neurotrophic and
is restricted to nervous tissue during most of
the course of infection. There is no viremia.
After inoculation, the virus may enter the pe-
ripheral nerves immediately, but usually there
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TABLE 2. EXECUTIVE SUMMARY OF GRADED RECOMMENDATIONS FOR VACCINATION OF INJURED PATIENTS
Rabies
Pre-exposure prophylaxis
Vaccination should be provided to persons at risk (laboratory workers, diagnosticians, veterinarians and their
staffs, animal control officers, rabies researchers, and some travelers to areas where rabies is prevalent) (Grade A)
Post-exposure prophylaxis
A five-dose regimen is recommended. Five one-milliliter doses of vaccine are given intramuscularly (deltoid
muscle) on days 0, 3, 7, 14, and 28 in conjunction with a single dose of human rabies immune globulin (HRIG) 20
IU/kg infiltrated into the wound on day 0. Any remaining HRIG should be administered IM at a site distant
from the vaccine site (Grade D)
Anthrax
Pre-exposure prophylaxis
Vaccination may be indicated for veterinarians and other high-risk persons handling potentially infected
animals in areas with a high incidence of anthrax. Routine vaccination of emergency first-responders, federal
responders, medical practitioners, and private citizens is not recommended (Grade B)
Post-exposure prophylaxis
Administration of the vaccine and antibiotics against B. anthracis is recommended following an aerosol
exposure to spores. Post-exposure vaccination should be administered as three injections of vaccine, beginning as
soon as possible, at 0, 2, and 4 weeks (Grade E)
Tetanus
Prophylaxis of acute wound
Administration of tetanus immune globulin (HTIG) 250 IU is recommended only for patients with tetanus-
prone wounds who have never completed a primary immunization series. The HTIG should be given at a site
different from the tetanus toxoid to avoid interaction (Grade B)
For small children, the routine dose of HTIG may be calculated by body weight (4 IU/kg). However, it may be
advisable to administer the entire 250 IU, because theoretically, the same amount of toxin will be produced in a
child’s as in an adult’s body (Grade B)
If a patient with an acute soft tissue injury has not been immunized previously, a tetanus toxoid booster is
required. The patient must have followup to complete the series. If the patient has been immunized previously, a
booster dose is given if the last dose was more than five years previously (for a tetanus-prone wound) or more
than 10 years previously (for a non-tetanus-prone wound). Patients with a contraindication to tetanus toxoid must
be managed with HTIG alone (Grade B)
Immunization of high-risk persons
The elderly, HIV-infected, or otherwise immunocompromised patient may not respond adequately to
vaccination alone. More liberal use of HTIG may be warranted for these patients, regardless of primary
immunization status. More frequent dosing of tetanus toxoid may help to sustain adequate antibody titers 
(Grade E)
Intravenous drug users may present with complaints unrelated to acute wounds. However, their drug use
should be considered a risk factor that requires consideration of tetanus prophylaxis (Grade E)
Vaccination after Splenectomy
The 23-valent polysaccharide pneumococcal vaccine is recommended for persons 2 to 64 years of age who have
functional or anatomic asplenia (Grade D)
High-risk individuals should be considered for vaccination with Haemophilus influenzae type B conjugate vaccine
(Grade D)
Asplenic patients should receive meningococcal vaccine (Grade D)
Timing and redosing
For patients undergoing elective splenectomy, vaccination should be performed at least two weeks before
surgery to maximize the antibody against T-cell-dependent immunogens (Grade C)
Patients who undergo emergency splenectomy should receive immunizations 14 days postoperatively 
(Grade D)
A single revaccination with the 23-valent polysaccharide pneumococcal vaccine should be given at least five
years after the first dose. No further dosing is recommended routinely (Grade D). 
There is currently no recommendation to revaccinate for H. influenzae type B or meningococcus
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is an incubation period during which the virus
is amplified. The virus then crosses the myo-
neural junction and enters the nervous system
through unmyelinated sensory and motor ax-
ons. Rabies can be prevented only by post-ex-
posure immunization during this incubation
period, before the virus enters the central ner-
vous system. The virus moves rapidly through
axons until it reaches the spinal ganglia. At this
time, the first symptoms of the disease (pain
and paresthesia at the wound site) may appear.
The virus then disseminates quickly in the cen-
tral nervous system, causing rapidly progres-
sive encephalitis that is fatal in the absence of
sometimes-heroic treatment measures [13].
Transmission. In nature, the rabies virus is la-
bile, being inactivated by sunlight, heat, desic-
cation, and other environmental factors. Thus,
it is not viable outside the host. Exposure oc-
curs when there is penetration of the skin by
teeth or direct transdermal or mucosal contact
with infectious material, such as brain tissue or
saliva. Almost all cases are caused by bites from
infected mammals.
All mammals are susceptible and can trans-
mit rabies virus, but true reservoirs, which are
responsible for long-term disease maintenance,
persist only among Carnivora and Chiroptera
(bats) [12]. Specific viruses are adapted to these
hosts and typically perpetuate infection within
a species by transmission before the host dies.
In North America, raccoons, skunks, bats,
foxes, coyotes, and bobcats are the primary
reservoirs. Unvaccinated domestic animals and
human beings become rabid after exposure to
such reservoirs. By definition, all reservoirs are
capable of transmitting infection, but not all po-
tential vectors are reservoirs. For example, live-
stock die of the disease before transmitting it.
Cats, usually infected by dogs or wild animals,
are effective vectors but do not sustain the dis-
ease [14].
In developed countries, the incidence of hu-
man exposure to rabid domestic animals has
decreased as a result of improved canine vac-
cination. Whereas more than 9,000 rabid dogs
were reported in the U.S. in 1944, fewer than
100 were identified in 2002 [12]. Because cats
are popular but less well supervised and less
often vaccinated than dogs, rabid cats now out-
number rabid dogs. Rabies in small mammals
such as mice and squirrels is rare, and trans-
mission from them to humans remains undoc-
umented. Larger rodents, such as woodchucks,
are more frequently reported to be rabid [14].
“Cryptic” human rabies cases, in which there
is no history of exposure to a rabid animal, are
now the norm in the U.S. Molecular character-
ization has determined that the majority of
these cases are associated with bat rabies
viruses [15]. Bat bites are not dramatic and may
not be appreciated when they occur or when
the patient is examined. In other cases, people
may recognize that a bite has occurred, but may
not comprehend its implications or may believe
that the risk of rabies is exceedingly low. Cer-
tain persons, such as young children or persons
with disabilities, may be unable to provide an
accurate history of a bite [16].
Vaccination of children younger than five years
The 7-valent pneumococcal conjugate vaccine is recommended for all children 24 to 59 months of age who are
at high risk for invasive pneumococcal infection. High-risk children include those with sickle cell disease and
other types of functional or anatomic asplenia. For high-risk children 24 to 59 months of age who have received
no previous dose of either the 23-valent or the 7-valent pneumococcal polysaccharide vaccine, two doses of the 
7-valent conjugate vaccine are recommended, to be given at an interval of six to eight weeks, followed by a single
injection of the 23-valent vaccine no less than six to eight weeks after the last dose of the 7-valent vaccine. An
additional dose of 23-valent vaccine is recommended three to five years after the last dose (Grade D)
High-risk children 24 to 59 months of age should also receive vaccination against meninococcus and H.
influenzae type B (Grade D)
Antibiotic prophylaxis is recommended for all children with sickle cell disease and functional or anatomic
asplenia, regardless of whether they have received pneumococcal immunization (Grade B)
Oral penicillin V potassium is recommended in a dose of 125 mg twice a day, until three years of age and in a
dose of 250 mg twice a day after three years of age. Children who have not experienced invasive pneumococcal
infection and have received recommended pneumococcal immunizations may discontinue penicillin prophylaxis
after five years of age (Grade B)
TABLE 2. EXECUTIVE SUMMARY OF GRADED RECOMMENDATIONS FOR VACCINATION OF INJURED PATIENTS (CONTINUED)
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Since 1960, exposures other than bites have
resulted in fewer than 35 documented human
rabies cases. Most of the reported cases were
attributable to poorly inactivated vaccine or to
organ transplantation. Although extremely un-
common, transplantation of tissue from a
donor with rabies will have disastrous conse-
quences for the transplant recipient, as has been
described recently [17]. No cases in human be-
ings after indirect, non-bite exposure, such as
touching a pet that may have been exposed to
a rabid animal, have been reported. Theoreti-
cally, human-to-human transmission is possi-
ble, but no cases have been documented among
healthcare workers [18].
Clinical presentation and diagnosis. The clinical
course of rabies in humans is acute, usually
progressing from initial symptoms to death
within two to three weeks, even with intensive
supportive care. The incubation period can
range from a few days to several years, de-
pending on the infecting strain. The period also
is believed to be inversely related to the size of
the inoculum and the proximity of the bite to
the central nervous system. The subsequent
clinical course can be described in three stages.
In the prodromal stage, the symptoms and
signs include fever, anorexia, nausea, vomiting,
and malaise. Approximately one-half of the pa-
tients develop pain or paresthesia at the wound
site. Within a few days, neurologic symptoms
such as anxiety, agitation, irritability, or in-
somnia may become manifest. The acute neu-
rologic stage follows, with objective signs of
central nervous system involvement. Most pa-
tients have “furious” rabies, characterized by
marked hyperactivity, disorientation, halluci-
nation, or bizarre behavior. This hyperactivity
later becomes intermittent and may be sponta-
neous or precipitated by tactile, auditory, or vi-
sual stimuli. Hydrophobia—spasm of the phar-
ynx and larynx provoked by drinking or the
sight of water—and aerophobia—a similar ef-
fect produced by air currents on the patient’s
face—are considered hallmarks of the disease.
Seizures may also appear during this stage, as
can dysfunction of the autonomic nervous sys-
tem. A few patients die during this stage, but
most go on to develop progressive paralysis
and eventually coma. In some patients, the par-
alytic state dominates the entire clinical picture.
Paralysis or paresis involves the proximal mus-
cles and can be accompanied by constipation,
urinary retention, or respiratory failure. In pa-
tients receiving intensive supportive care, the
average duration of illness between the onset
of paralysis and death is approximately seven
days. Once neurologic symptoms have devel-
oped, survival is rare. With one exception [19],
the only survivors recorded so far had received
post-exposure prophylaxis or had been vacci-
nated previously [18].
Human rabies in the U.S. is rare, but also un-
derdiagnosed. The diagnosis can be elusive if
a history of animal exposure is not obtained.
Hydrophobia and aerophobia, pathognomic
when present, may be absent. Rabies, along
with tetanus, Guillain-Barré syndrome, trans-
verse myelitis, and toxic ingestion, should be
considered in the differential diagnosis of any
rapidly progressive encephalitis even if the his-
tory of bite is not available. It also is important
to exclude other treatable encephalitides such
as herpes encephalitis [20].
Routine laboratory tests and diagnostic
studies are of little value in the diagnosis of
rabies. Examination of the cerebrospinal fluid
may show leukocytosis, but protein and glu-
cose concentrations are often normal. Com-
puted tomography and magnetic resonance
imaging scans may be normal even in the pres-
ence of advanced rabies encephalitis. There-
fore, specific diagnostic tests are necessary
that include virus antigen detection, serologic
studies, virus culture, and histopathologic
examination. Virus antigen can be detected
when a 6-mm punch biopsy of the skin from
the nape of neck is stained with immunofluo-
rescent rabies antibody, which reveals the
antigen in sensory nerve endings at the base
of hair follicles. This test is positive in 50% of
patients in the first week of illness. Immuno-
fluorescent antibody staining of the epithelial
cells of the cornea (corneal impression test) can
also help with the diagnosis. Seroconversion,
in unvaccinated individuals, usually happens
in the second week of illness, although it can
be delayed by several days. In individuals
who have been vaccinated, it is difficult to dis-
tinguish between infection and vaccination
serologically, but measurable spinal fluid
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titers and very high serum antibody titers sug-
gest infection. Rabies virus also can be cul-
tured from saliva, throat, tracheal secretions,
cerebrospinal fluid, or brain biopsy specimens,
but the yield is low. Postmortem examination
of the brain reveals perivascular inflammation
of the gray matter, neuronal degeneration, and
the characteristic cytoplasmic inclusions called
Negri bodies [13].
Description of rabies vaccine and human rabies
immunoglobin. The Imovax Rabies Vaccine®
(Aventis Pasteur, Lyon, France) is a sterile, sta-
ble, freeze-dried suspension of rabies virus pre-
pared from strain PM-1503-3M (Wistar Insti-
tute, Philadelphia, PA). The virus is harvested
from infected human diploid cells, concen-
trated by ultrafiltration, and inactivated by
beta-propiolactone. One dose of reconstituted
vaccine contains less than 100 mg of albumin,
less than 150 mcg of neomycin sulfate, and 20
mcg of phenol red indicator. There is no preser-
vative or stabilizer. The vaccine therefore
should be used immediately after reconstitu-
tion or discarded. The potency of one dose (1
mL) is 2.5 IU of rabies antigen.
A single dose (20 IU/kg) of human rabies im-
mune globulin (HRIG) should be given at the
beginning of anti-rabies prophylaxis to provide
protection for the first two weeks until the vac-
cine elicits an antibody response. All patients
should receive HRIG except those who have
previously received a cell culture vaccine as
pre-exposure or post-exposure prophylaxis or
who have documented rabies antibody titers
after receiving another vaccine [20]. Even if
there is a substantial delay between exposure
and initiation of post-exposure prophylaxis,
HRIG should be given. It can be given as late
as the seventh day after vaccine administration,
after which the vaccine should have elicited an
antibody response. If possible, the full dose of
HRIG should be infiltrated into the wound, and
any remaining volume should be administered
IM at a site distant from the vaccine site. The
immune globulin should never be delivered in
the same syringe as the vaccine [20].
Adverse reactions. Once initiated, rabies pro-
phylaxis should not be interrupted or discon-
tinued because of local or mild systemic reac-
tions to the vaccine. Reactions after vaccination
with human diploid cell vaccine (HDCV) are
less common than with previous vaccines. In a
study using five doses of HDCV, local reactions
such as pain, erythema, and swelling or itch-
ing at the injection site were reported by ap-
proximately 25% of recipients, and mild sys-
temic reactions such as headache, nausea,
abdominal pain, muscle aches, or dizziness
were reported by 20%. A small percentage of
recipients experienced immune complex reac-
tions characterized by generalized urticaria,
arthralgias, arthritis, angioedema, or malaise
developing typically 2 to 21 days after admin-
istration of the booster dose of HDCV. These
reactions have been attributed to the presence
of beta-propiolactone-altered human albumin
in the HDCV [21,22]. Local reactions usually
can be managed with anti-inflammatory
agents. Steroids should not be given because
they can interfere with the development of im-
munity to the vaccine. When a person has a se-
rious hypersensitivity reaction to the vaccine,
revaccination should be undertaken only after
careful consideration of the risk of acquiring ra-
bies and then should be supervised carefully,
with epinephrine readily available to counter-
act any anaphylactic reactions [23].
The HRIG can cause pain and low-grade
fever. There have been no specific reported ad-
verse reactions to HRIG, although immune
globulins have been associated with angioneu-
rotic edema, nephrotic syndrome, and ana-
phylaxis [20].
Evidence-based recommendations. The efficacy
of pre-exposure immunization was docu-
mented by high-titer antibody responses to the
Imovax Rabies Vaccine in trials conducted in
England, Germany, France, and Belgium
[24–27]. Seroconversion often was obtained
with only one dose. With two doses one month
apart, 100% of the recipients developed specific
antibody, with a geometric mean titer of ap-
proximately 10 IU/mL. In the U.S., Imovax Ra-
bies Vaccine resulted in geometric mean titers
of 12.9 IU/mL at day 49 and 5.1 IU/mL at day
90 when three doses were given intramuscu-
larly over one month [28].
Post-exposure efficacy of the Imovax Rabies
Vaccine was proved during clinical experience
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in Iran, where 45 persons received the vaccine
after being bitten by rabid dogs or wolves. All
except one also received one injection of HRIG.
In contrast to the experience with other vac-
cines, this treatment protected all of the indi-
viduals against rabies [29].
The ACIP publishes protocols for prevention
of human rabies in the U.S. [20]. The informa-
tion presented in this article is consistent with
the ACIP guidelines. The recommendations of
the American Academy of Pediatrics are in ac-
cord with those of the ACIP. Vaccine doses dur-
ing post-exposure prophylaxis are equivalent
in adults and children [30].
Pre-exposure prophylaxis. The ACIP recom-
mends three injections of 1 mL each of Imovax
Rabies Vaccine, one on day zero, one on day
seven, and one on either day 21 or day 28. It is
recommended that vaccination be provided to
persons at risk (laboratory workers, diagnosti-
cians, veterinarians and their staffs, animal con-
trol officers, rabies researchers, and some trav-
elers to areas where rabies is prevalent) before
exposure [20,28] (Grade A). This strategy sim-
plifies the management of a subsequent expo-
sure because fewer vaccine doses are needed
and HRIG is not required. Routine serologic
analysis for verification of the presence of
virus-neutralizing antibody is unnecessary af-
ter primary vaccination unless major interrup-
tions in the schedule occur or questions arise
about immune competence. Thereafter, the
need for routine booster vaccination may be
monitored by serologic testing performed
every six months to two years as long as the
person remains at risk. If titers fall below a min-
imal acceptable value (complete neutralization
at a serum dilution of 1:5), a single vaccine
booster dose is administered. Persons who
work with rabies virus in research laboratories
or vaccine production facilities are at highest
risk of exposure and should have their rabies
antibody titers checked every six months.
Other laboratory workers (those performing ra-
bies diagnostic testing), spelunkers, veterinari-
ans and their staffs, and animal control and
wildlife officers in areas where animal rabies is
enzootic, also should have antibody measure-
ments done every two years [31].
Post-exposure prophylaxis. Bites from bats and
high-risk wild carnivores such as raccoons,
skunks, foxes, bobcats, and coyotes warrant
consideration of immediate post-exposure pro-
phylaxis. In the case of direct contact between
a person and a bat, the possibility of a bite
should be considered unless the exposed per-
son can be reasonably certain that a bite did not
occur. Post-exposure prophylaxis should be
considered for persons who were in the same
room as a bat, and who might be unaware or
unable to communicate that a bite occurred
[30]. Rabies has been reported in large rodents
(woodchucks and beavers) in areas where ra-
bies is enzootic. Rabies has been diagnosed
rarely in small mammals such as rabbits and
small rodents (squirrels, chipmunks, rats, ham-
sters, gerbils, guinea pigs, and mice), and there
has never been a documented case of trans-
mission from these small mammals to a human
being. Post-exposure prophylaxis may be con-
sidered for the latter in unusual circumstances
(a bite from a small mammal with a history and
clinical signs compatible with rabies), unless
the animal tested negative. An apparently
healthy dog, cat, or ferret that bites a person
should be confined and observed daily for ten
days. The animal should not receive rabies vac-
cine during the observation period. A veteri-
narian should evaluate the animal at the first
sign of illness. Management of animals other
than dogs, cats, and ferrets depends on the
species, the circumstances of the bite, the local
rabies epidemiology, and the biting animal’s
history, health status, and potential for expo-
sure to rabies. Because prior vaccination of any
animal may not be 100% effective, current vac-
cination does not preclude the necessity for an
observation period, or as warranted, euthana-
sia and testing. If the animal exhibits signs of
rabies during the ten-day observation period,
the exposed person should immediately begin
to receive prophylaxis, and the animal should
be euthanized and its brain tissue tested for ra-
bies. If the animal is confirmed to have rabies,
post-exposure prophylaxis should be com-
pleted, whereas if the test results are negative,
post-exposure prophylaxis can cease. Diagnos-
tic testing of brain tissue should be completed
within 24–48 h so that a decision about start-
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ing post-exposure prophylaxis can be made. If
testing will take longer, prophylaxis should be
started, pending the results of testing [30].
Post-exposure prophylaxis consists of three
primary elements: Wound care, infiltration of
HRIG, and vaccine administration. Immediate,
thorough washing of all bite wounds and
scratches with soap and water is perhaps the
most effective measure for preventing rabies.
In experimental animals, local wound cleans-
ing markedly reduces the likelihood of rabies
[32]. Post-exposure anti-rabies immunization
should always include administration of HRIG
and vaccine, with one exception. Persons who
have been immunized previously with the rec-
ommended pre-exposure or post-exposure reg-
imens of HDCV, or who have been immunized
with other types of vaccines and have a docu-
mented adequate rabies antibody titer, should
receive vaccine only [30].
The ACIP recommends a five-dose regimen
for post-exposure prophylaxis. Five 1-mL
doses of Imovax Rabies Vaccine are given in
the deltoid muscle on days 0, 3, 7, 14, and 28
in conjunction with a single dose of HRIG 20
IU/kg on day 0. As much as possible of the
dose of HRIG should be infiltrated into the
wound. Any remaining volume should be ad-
ministered IM at a site distant from the vaccine
site [20, 29] (Grade D).
Anthrax
Biological warfare. The clinical disease known
as anthrax is caused by Bacillus anthracis, a
gram-positive, spore-forming bacillus capable
of infecting human and animal hosts. Several
factors affect the destructive capabilities of an-
thrax as a biological weapon. The delivery of
spores has been a major obstacle to the creation
of widespread anthrax contamination. Spores
can be spread easily in the air by missiles, rock-
ets, aerial bombs, or sprayers, but the accom-
panying explosions damage the anthrax parti-
cles considerably [33]. Particle size also affects
virulence and infective potential. When a par-
ticle is larger than 5–10 micrometers, infectiv-
ity may decrease substantially, as the 8,000 to
10,000 spores necessary for infection may not
be inhaled. One- to two-micrometer spores are
highly lethal, but the creation of stable spores
smaller than five micrometers has not been
reported outside state-sponsored laboratories
[33]. Also, the concentration of the powder
affects the quality of the anthrax. The U.S. 
has produced the most concentrated anthrax
known, with as many as one trillion spores per
gram. Lastly, clumping of multiple spores lim-
its wide-spread dissemination. To limit this
clumping, sophisticated processing is carried
out with substances such as silica and treat-
ment to offset the electrostatic charge of the
particles to allow maximum dispersal. Anthrax
spores that are smaller than five micrometers
and have been treated to prevent clumping and
then concentrated are referred to as “high-
grade” or “weapons-grade” anthrax [34].
Pathogenesis. Anthrax is worldwide in preva-
lence and affects primarily herbivores that
while grazing ingest spores imbedded in the
soil, which may harbor the bacteria for years.
In humans, the anthrax toxin consists of three
proteins that combine for the lethal effect (see
below). The toxin affects neutrophils and
macrophages, inhibiting bacterial phagocytosis
and preventing the oxidative burst of neu-
trophils [35].
Clinical presentation. The human disease has
three forms: Cutaneous, pulmonary, and gas-
trointestinal. The incubation period is generally
2–60 days. In developed countries, 95% of af-
fected patients have the cutaneous form, ac-
quired by contact with infected goats, sheep, or
cattle. The cutaneous form starts as a painless
pruritic papule resembling an insect bite, some-
times surrounded by vesicles. This papule de-
velops into an ulcer with a necrotic center. The
lesions usually start on the extremities and
spread to the head and neck. Lymphadenopa-
thy with systemic signs and symptoms of fever,
malaise, and headache may accompany the cu-
taneous lesions. The case-fatality rate of cuta-
neous anthrax is 20% without antibiotic treat-
ment but less than 1% with treatment [36].
Many public health and U.S. State Depart-
ment officials believe that the most likely sce-
nario for a biological attack using anthrax
would be a release of aerosolized spores over
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densely populated areas, causing large num-
bers of cases of pulmonary anthrax [33]. The
pulmonary or inhalational form can result from
the inhalation of concentrated spores in a bio-
logical attack, but it has also been described in
handlers of Pakistani goat hair in textile work-
ers in Switzerland and the U.S. [37]. The pre-
sentation of the pulmonary form is classically
biphasic but can be variable. Early symptoms
can mimic an upper respiratory infection with
a dry cough, low-grade fever, and malaise for
several days. As the symptoms become appar-
ent, the process can involve the hilar and me-
diastinal lymph nodes, causing substernal
pain, bloody pleural effusions, and a wide me-
diastinum on chest radiography. A fulminant
acute phase develops later with severe respi-
ratory distress, high fever, meningitis, and
shock. Hemorrhagic mediastinitis is consid-
ered a pathognomic sign. The pulmonary form
is invariably fatal if untreated and 80% fatal if
treated after the onset of symptoms [38].
Ingestion of contaminated meat causes gas-
trointestinal anthrax. Some of the abdominal
manifestations are nonspecific, including ab-
dominal pain, fever, nausea, and vomiting.
More severe symptoms can also occur, includ-
ing upper or lower gastrointestinal bleeding or
peritonitis. The gastrointestinal type can
progress to death within five days. It has never
been described in the U.S. [39].
On recognizing the symptoms of anthrax,
health care workers should send any affected
body fluids for culture. These specimens would
include material from vesicles, pleural fluid,
cerebrospinal fluid, and stool. Standard blood
cultures should yield large gram-positive
bacilli within 6–24 h, and the clinical laboratory
should be alerted to the possibility of anthrax
so the organism is not dismissed as a skin con-
taminate. Sputum culture and gram stain are
unlikely to be diagnostic. An enzyme-linked
immunosorbent assay (ELISA) is available only
in a national reference laboratory [33,37].
Vaccine description. The anthrax vaccine is an
inactivated cell-free filtrate of B. anthracis ad-
sorbed to aluminum hydroxide (BioThrax®,
Bioport Corporation, Lansing, MI). Anthrax
manifestations are the result of three major
toxins: Protective antigen (PA), lethal factor
(LF), and edema factor (EF). Lethal factor is a
zinc metalloprotease that inhibits mitogen-
activated protein kinase. Edema factor is a
calmodulin-dependent adenylate cyclase that
generates cyclic adenosine monophosphate in
the cytoplasm of eukaryotic cells. Protective
antigen, the only major antigen in the vaccine
[40,41], is an 82-kD protein that binds to re-
ceptors on most mammalian cells. It is then
cleaved by a cell surface protease, exposing a
site that binds competitively to either EF or LF,
creating a complex that enters the cell.
The vaccine is recommended for administra-
tion to adults 18 to 65 years of age in six sub-
cutaneous injections at 0, 2, and 4 weeks and at
6, 12, and 18 months. An annual booster injec-
tion is recommended to maintain immunity.
Shorter vaccination schedules are being inves-
tigated. With this administration schedule, an-
tibody titers to PA peak within 14 days after
the third dose [42], and 95% of vaccinated in-
dividuals seroconvert with a four-fold increase
in anti-PA titer. However, the protective titer
has not been defined, and the duration of pro-
tection is not known [43].
Vaccine efficacy. Because of the infrequent oc-
currence of natural infection and the unpre-
dictability of human-induced exposure, the ef-
ficacy of the vaccine is unclear. Only one
controlled trial in human beings has been pub-
lished, and it is more than 40 years old [44].
This was a single-blind, placebo-controlled trial
of approximately 800 mill workers at risk of in-
fection from animal products (379 received vac-
cine and 414 received the placebo injection).
The vaccine efficacy was 92.5% (the lower 95%
confidence limit was 65%).
Adverse reactions. Many individuals have re-
ceived the vaccine in military and civilian pro-
grams in recent years, providing a reasonable
assessment of the risk of adverse effects. In a
summary of prelicensure vaccine administra-
tion to 7,000 individuals, severe local reactions
occurred in 1%, moderate local reactions
(edema and induration) in 2%, and mild local
reactions in 20% of recipients. Systemic reac-
tions (e.g., fever, chills, body aches) were re-
ported by fewer than 0.1% of vaccinees [44].
From 1990 to 2000, 1,544 adverse events were
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reported to the Vaccine Adverse Event Re-
porting System (VAERS), of which 5% were se-
rious [45]. The most frequent were injection site
hypersensitivity, injection site edema, pain,
headache, arthralgia, and pruritus. There were
two reports of anaphylaxis, and two deaths
were associated with the vaccine, but a causal
relationship was not established. The incidence
of adverse effects per dose of vaccine cannot be
ascertained from the available data.
More than 425,000 military service personnel
received more than 1.6 million vaccine doses
from 1998 to 2000, and “no patterns of unex-
pected local or systemic adverse events have
been identified” [46]. A review of the experi-
ence of 1,583 employees of the Army Medical
Research Institute of Infectious Diseases who
received the vaccine over the past 25 years
demonstrated that 1% of inoculations were as-
sociated with systemic effects [47]. The most
frequent adverse effects were headache (0.4%)
and local or injection site reactions (2.6%). In
one series of almost 5,000 vaccinated military
personnel, most adverse events were localized,
minor, and self-limited, including arthralgia,
headache, and fatigue [46].
The potential for congenital anomalies in
children when the vaccine is administered to
their mothers in the first trimester of pregnancy
has not been studied. Therefore, the vaccine is
not licensed or recommended for use in preg-
nancy and is rated Pregnancy Category D by
the Food and Drug Administration. The ACIP
recommends that pregnant women be vacci-
nated against anthrax only if the potential ben-
efits outweigh the potential risk to the fetus
[38].
The Institute of Medicine concluded that al-
though no significant adverse effects of the an-
thrax vaccine have been reported, the evidence
is inadequate to determine whether an associ-
ation exists between anthrax vaccination and
long-term health outcomes [48]. The CDC con-
cluded that the chronic multi-system illness ex-
perienced by some Persian Gulf War veterans
was not associated with the vaccine or other
specific anthrax exposures [49].
Evidence-based recommendations. There is in-
sufficient evidence to document the efficacy of
the anthrax vaccine in individuals who are ex-
posed or have high risk of exposure to anthrax.
Pre-exposure efficacy has been documented
only in mill workers who were exposed in the
workplace [44]. Despite the lack of clinical trial
data, anthrax vaccine is recommended in cer-
tain individuals by the ACIP [38,50].
Pre-exposure prophylaxis. For pre-exposure
prophylaxis, anthrax vaccine use should be
based on quantifiable risk of exposure. The vac-
cine should be administered by subcutaneous
injection at 0, 2, and 4 weeks and then at 6, 12,
and 18 months [38]. Groups at risk for repeated
exposure should be given priority for vaccina-
tion, including: All U.S. active and reserve-duty
military personnel; laboratory personnel han-
dling environmental specimens; workers who
will be making repeated entries into known B.
anthracis spore-contaminated areas after a ter-
rorist attack; and workers in other settings in
which repeated exposure to aerosolized B. an-
thracis spores might occur. Laboratory workers
using standard Biosafety Level 2 practices in the
routine processing of clinical samples or en-
vironmental swabs are not considered at in-
creased risk. Routine vaccination of veterinari-
ans in the U.S. is not recommended because of
the low incidence of animal cases. However, vac-
cination might be indicated for veterinarians and
other high-risk persons handling potentially in-
fected animals in areas with a high incidence of
anthrax. Routine vaccination of emergency first-
responders, federal responders, medical practi-
tioners, and private citizens is not recommended
[38,44,50,51] (Grade B).
Post-exposure prophylaxis. Post-exposure vac-
cination should be administered as follows:
Three injections of vaccine, one as soon as pos-
sible and the others at two and four weeks.
Post-exposure prophylaxis with the vaccine
and antibiotics against B. anthracis is recom-
mended following an aerosol exposure to
spores [38] (Grade E). The vaccine is effective
at preventing disease in non-human primates
after exposure [52,53].
A major issue with post-exposure prophy-
laxis is how long antimicrobial therapy should
be given when the vaccine is used. The ACIP
recommends at least a 30-day course of
ciprofloxacin or doxycycline post-exposure for
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persons who have been vaccinated partially or
fully. Antibiotics should be administered at
least until the third vaccine dose is given [38].
Although the shortened vaccine regimen has
been effective post-exposure when co-adminis-
tered with antibiotics, the duration of protec-
tion from vaccination is not known. Because
human-to-human transmission has not been
documented, contacts and friends do not need
prophylaxis unless they also were exposed to
the aerosol [38].
Tetanus
Epidemiology, etiology, and pathophysiology.
Since 1975, fewer than 100 cases of tetanus have
been reported annually in the U.S., and for the
past ten years, the number has averaged less
than 50 per year [54]. Thus, tetanus has become
rare, ranking in frequency behind botulism,
brucellosis, leprosy, Rocky Mountain spotted
fever, and typhoid fever. This situation can be
attributed to several factors, including a de-
crease in environmental exposure to Clostrid-
ium tetani, better management of tetanus-prone
wounds, and universal immunization of chil-
dren and military personnel. Because the pri-
mary tetanus toxoid (TT) series induces excel-
lent immune memory, booster doses reliably
result in a brisk anamnestic antibody response,
even when intervals of 20 years or more have
elapsed since the last dose. Therefore, an anti-
toxin concentration below 0.1 IU/mL (the gen-
erally accepted minimum protective concen-
tration) is strong evidence that either the
individual never received a primary series of
TT or has not received a booster dose in the
previous decade [55].
A national population-based serologic sur-
vey conducted from 1988 to 1991 showed sero-
logic evidence of immunity declining from 80%
among persons aged 6 to 39 years to 28%
among persons 70 years or older [3]. In national
health interview surveys, only 27–36% of indi-
viduals age 65 years or older reported receiv-
ing a tetanus vaccination during the previous
ten years. More than 90% of the small number
of remaining tetanus cases in the U.S. occur in
individuals who do not know their immuniza-
tion status or report having received less than
a full primary immunization series [56].
Thus, despite serologic evidence that large
numbers of adults are susceptible, tetanus is
rare among individuals who have had their full
primary series at any previous time. This fact
suggests strongly that the protective antitoxin
standard of 0.1 IU/mL is not nearly as reliable
as a history of full immunization in predicting
protection from disease. Additional evidence of
the long-term protective effect of the primary
immunization series is the lifelong ameliora-
tion of disease severity. In more than 20 years
of CDC data, no deaths have been reported
from tetanus among individuals who have
been fully immunized at any time [56–58].
Universal diphtheria-tetanus (acellular)-per-
tussis (DTP/DTaP) immunization of children
has all but eliminated pediatric tetanus except
among immigrant children and other pockets
of subpar vaccine delivery, and tetanus has be-
come primarily a disease of adults who have
never been immunized fully. Special risk fac-
tors include injection drug use and chronic
wounds, in addition to acute traumatic injuries.
The recommendations for the use of TT and
tetanus immune globulin in the treatment of
tetanus-prone wounds remain intact and
would not be affected by a decrease in the avail-
ability or utilization of tetanus boosters [56].
Tetanus-diphtheria toxoid (Td) and TT are
used almost exclusively in adults, and approx-
imately 16 million doses are distributed annu-
ally in the U.S. [54]. Approximately one-half of
the total is delivered as part of routine care (de-
cennial booster) and the other half in the man-
agement of tetanus-prone wounds.
Clostridium tetani is a spore-forming, gram-
positive bacillus. Although the organism is an
obligate anaerobe, its spores remain viable at
ambient oxygen concentrations. The spores are
resistant to extremes in temperature and hu-
midity and can survive indefinitely. Spores are
ubiquitous in soil and in the feces of many
animals and human beings [59]. Carried into
wounds along with soil, spores may not germi-
nate immediately because of unfavorable local
tissue conditions only to be activated after the
wound has healed, which may account for the
cases of tetanus that have no identifiable source.
When conditions favor anaerobic prolifera-
tion, the spores germinate into mature bacilli,
which then elaborate the toxins tetanolysin and
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tetanospasmin. Tetanolysin has an unclear role
in clinical tetanus; it may contribute to an
anaerobic environment by damaging viable tis-
sue [60]. Tetanospasmin is primarily responsi-
ble for the clinical manifestations of tetanus,
entering peripheral nerves and traveling via
axonal retrograde transport to the central ner-
vous system. Tetanospasmin then enters pre-
synaptic neurons and disables neurotransmit-
ter release, most importantly of the inhibitory
neurotransmitters gamma-aminobutyric acid
(GABA) and glycine. This results in disinhi-
bition of end-organ neurons such as motor
neurons and those of the autonomic nervous
system, accounting for the muscle spasms char-
acteristic of tetanus and the autonomic insta-
bility of severe tetanus. The rapidity of disease
onset correlates with its severity. Recovery in-
volves synthesis of new presynaptic compo-
nents and their transport to the distal axon, ac-
counting for the typical 2–3 week period before
clinical improvement begins [60].
Clinical presentation and diagnosis. There are
four clinical forms of tetanus, depending on the
extent and location of the involved neurons:
Generalized, local, cephalic, and neonatal. In
the U.S. and other developed countries, gener-
alized tetanus is the most common form, oc-
curring in 80% of cases [56]. In 50–75% of cases,
the initial symptom is trismus or “lockjaw” sec-
ondary to masseter muscle spasm. Risus sar-
donicus, the “ironical smile” of tetanus, occurs
because of facial muscle contraction. Nuchal
rigidity and dysphagia also may be initial com-
plaints. As the disease spreads, generalized
muscle spasms occur, either spontaneously or
in response to minor stimuli such as touch or
noise. Opisthotonus, a tonic contraction simi-
lar to decorticate posturing, is described classi-
cally. Severe spasms can result in vertebral and
long bone fractures and detachment of tendons
from their insertions. Unfortunately for the pa-
tient, mental status is not affected, and the
spasms are accompanied by severe pain [61].
In the acute phase, death results from acute
respiratory failure caused by diaphragmatic
paralysis or laryngeal spasm [60]. With inten-
sive medical intervention, including the use of
neuromuscular blockade and mechanical ven-
tilation, early death can be averted. In patients
surviving beyond the acute phase, autonomic
instability becomes the major cause of death,
with a fatality rate of 11–28% [62]. Autonomic
instability appears several days after the onset
of generalized spasms and manifests most im-
portantly as labile hypertension, tachycardia,
and pyrexia. Dysrhythmias and myocardial in-
farction are the most common fatal events. The
exact mechanism of the late-phase syndrome is
unclear but likely involves disinhibition of the
sympathetic nervous system. Case reports have
documented elevated concentrations of cate-
cholamines in patients with autonomic insta-
bility; concentrations decrease with successful
treatment [63,64].
Local tetanus presents as persistent muscle
rigidity close to the site of injury. The rigidity
may linger from weeks to months but often re-
solves without sequelae. A caveat is that what
appears to be localized tetanus may instead be
the first sign of generalized tetanus. Local
tetanus is responsible for 13% of all tetanus
cases, and its case-fatality rate is about 1% [65].
Cephalic tetanus is an uncommon variant of
localized tetanus that involves the cranial
nerves and accounts for 6% of all cases of
tetanus [56]. Cephalic tetanus uniquely results
in nerve palsies as well as muscle spasms. The
seventh cranial nerve (CNVII) is most often in-
volved, followed by CNVI, CNIII, CNIV, and
CNXII in decreasing order of frequency.
Cephalic tetanus also presents as trismus, but
in 42% of cases, cranial nerve deficits precede
trismus. In such cases, cephalic tetanus is eas-
ily misdiagnosed. With its predilection for 
CNVII, it commonly mimics Bell’s palsy. Head
trauma and otitis media are commonly cited
etiologies. About two-thirds of patients
progress to generalized tetanus, and the over-
all mortality rate is 15–30% [66].
Neonatal tetanus is generalized tetanus that
occurs around the end of the first week of life.
Symptoms begin with nonspecific irritability
and poor feeding and progress rapidly to gen-
eralized spasms. The portal of entry is the
freshly cut umbilical cord. The risk of con-
tracting neonatal tetanus is directly related to
the cleanliness of delivery conditions and to
maternal immunization because passive trans-
fer of maternal immunoglobins is protective
[67]. Mortality is high, 50–100%, because of the
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high load of toxin in relation to body weight.
Neonatal tetanus occurs largely in developing
countries, with an estimated 80% of cases con-
centrated in twelve countries in Africa and
Asia [68].
The diagnosis of tetanus must be made on
clinical grounds alone, as there are no labora-
tory tests that can diagnose or rule it out. A pro-
tective serum antitoxin antibody concentration,
commonly accepted as 0.1 IU/mL, makes the
diagnosis of tetanus unlikely, although not im-
possible, as there are reports of tetanus in im-
munocompetent individuals having protective
antibody concentrations. Unfortunately, anti-
toxin antibody values are not likely to be avail-
able at the time management decisions must be
made. Fortunately, the presentation of tetanus
is so characteristic that a presumptive diagno-
sis is possible in most cases [69].
The differential diagnoses are few. Trismus
can be caused by peritonsillar or odontogenic
abscesses, which can be excluded by history
and physical examination. Dystonic reactions
can present as trismus. A positive response to
diphenhydramine will quickly differentiate
non-specific trismus from tetanus. Strychnine
poisoning can resemble generalized tetanus
grossly. Strychnine disables glycine release, as
does tetanospasmin, but does not affect GABA
release. There were 40 cases of strychnine poi-
soning in the U.S. in 1997, an incidence similar
to that of tetanus [70]. In most cases, timely
measurement of the blood strychnine concen-
tration will not be available to the emergency
physician. Nevertheless, the test should be or-
dered for inpatient followup. Hypocalcemia
causing tetany is another mimic, which can eas-
ily be excluded with laboratory testing. Other
entities that cause diffuse muscle spasm, such
as seizures and encephalopathies, are accom-
panied by changes in mental status. Processes
that affect muscles locally, such as myopathies
or neuropathies, tend to cause weakness rather
than spasm and rigidity.
Description of tetanus toxoid, tetanus-diphtheria
toxoid, and human tetanus immune globulin.
Tetanus is preventable with proper use of TT
and human tetanus immune globulin (HTIG).
Tetanus toxoid is an inactivated form of tetano-
spasmin available in three forms, variably com-
bined with diphtheria and pertussis vaccine:
DTaP, Td, and TT. DECAVAC® (Tetanus and
Diphtheria Toxoids Absorbed for Intramus-
cular Injection; Aventis Pasteur) is a sterile
suspension of aluminum-precipitated toxoids
in isotonic sodium chloride solution. Tetanus
and diphtheria toxins produced during the
growth of cultures are detoxified with formal-
dehyde and then purified separately by serial
ammonium sulfate fractionation and diafiltra-
tion [67].
The DECAVAC vaccine is supplied in a unit
dose of 0.5 mL in a preservative-free syringe.
Seroprevalance studies indicate that one-half or
more of adults in the U.S. lack what is consid-
ered a protective antitoxin concentration (0.1
IU/mL) against diphtheria [71,72]. Despite the
serologic evidence of susceptibility and the
corollary that most adults have not complied
with the decennial booster recommendation,
diphtheria remains a disease of negligible inci-
dence in the U.S. [67]. Because diphtheria has
been a pediatric disease historically, the focus
of diphtheria immunization programs has been
children. Before the Td combination was de-
veloped in the mid-1960s, there was no recom-
mendation for diphtheria boosters for adults.
The adult diphtheria toxoid recommendation
came about because of the availability of the
combined Td product rather than an indepen-
dent concern about diphtheria [73]. Tetanus-
diphtheria toxoid is the recommended prepa-
ration for active tetanus immunization and
wound management of patients older than
seven years. In such persons, Td is preferred to
single-antigen TT to enhance diphtheria pro-
tection [67].
Tetanus immune globulin (BayTet®; Bayer
Biological Products, Research Triangle Park,
NC) is a sterile solution of tetanus hyper-
immune globulin for intramuscular adminis-
tration. Tetanus immune globulin is prepared
by cold ethanol fractionation from the plasma
of donors immunized with TT. The inactivation
and removal of enveloped and non-enveloped
viruses during the manufacturing process has
been validated in laboratory studies [67].
Tetanus immune globulin supplies passive im-
munity to those individuals who have low 
or no immunity. The antibodies neutralize the
free form of the powerful exotoxin produced
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by this bacterium. Historically, such passive
protection was provided by antitoxin derived
from equine or bovine serum. However, the
foreign protein in these products often pro-
duced severe allergic manifestations, even in
individuals who demonstrated negative skin or
conjunctival tests prior to administration. Esti-
mates of the frequency of these foreign protein
reactions after injection of equine antitoxin
range from 5–30%. If passive immunization 
is needed, intramuscular injection of HTIG is
therefore the treatment of choice, as it provides
longer protection than antitoxin of animal ori-
gin and causes fewer adverse reactions [74].
Consisting of immunoglobulin (Ig)G, its half-
life of 25 days ensures long-lasting protection
[75]. Intradermal injection (not recommended)
causes local irritation that does not represent
an allergy to HTIG. Intravenous injection can
cause hypotension.
Adverse reactions. Common adverse reactions
to TT, including erythema, swelling, and ten-
derness at the injection site, are minor and of
no long-term consequence. In a clinical study
involving individuals six years of age and
older, 19% of vaccinees noted local reactions,
whereas 2% had systemic reactions consisting
of headache, malaise, or temperature elevation.
Arthus-type hypersensitivity reactions, charac-
terized by severe local reactions generally start-
ing 2–8 h after the injection, may follow receipt
of TT. Such reactions may be associated with
high concentrations of circulating antitoxin in
persons who have had overly frequent injec-
tions of TT [76].
Patients who give a history of allergy to
tetanus vaccine are most likely referring to a lo-
cal or nonspecific systemic reaction. These
events are not contraindications to receiving
TT. Other false contraindications include mild,
acute illness; fever; and a family history of an
adverse reaction to vaccination. Anaphylactic
reactions, neuropathies, and encephalopathies
are rare and constitute the only true contra-
indications to TT. Patients with a history of ana-
phylaxis should be referred for skin testing be-
cause they may no longer be reactive and if not,
can receive future vaccinations [67].
Adverse reactions to properly administered
HTIG are rare and consist largely of discomfort
at the injection site and a slight temperature el-
evation. A history of a severe adverse reaction
likely represents previous use of equine anti-
toxin, which has a 10% incidence of serum sick-
ness and a 1/100,000 incidence of fatal ana-
phylaxis [75]. Human tetanus immune globulin
is widely available in the U.S., so that equine
antitoxin is rarely used. In contrast, equine an-
titoxin is used extensively in developing coun-
tries because of greater availability and afford-
ability.
Evidence-based recommendations. Spores of C.
tetani are ubiquitous, but serologic tests indi-
cate that naturally acquired immunity to
tetanus toxin does not occur in the U.S. Thus,
universal primary vaccination with subsequent
maintenance of adequate antitoxin concentra-
tions by means of appropriately timed boost-
ers is necessary to protect all age groups [67].
After adequate immunization with TdT, it is
believed that protection persists for at least 10
years. Protection against disease is attributable
to the development of neutralizing antibodies
to tetanus and diphtheria toxin.
The efficacy of TdT used in DECAVAC vac-
cine was determined by comparison with a
serological correlate of protection (0.1 IU/mL)
established by the Panel on Review of Bacter-
ial Vaccines and Toxoids [54,77]. A clinical
study to evaluate the serological responses and
adverse reactions was performed in individu-
als six years of age and older. Protective con-
centrations of antibody were achieved in more
than 90% of the study subjects after primary
immunization with both components. Booster
effects were achieved in 100% of the individu-
als with existing antibodies [78].
Talan et al. measured the prevalence of pro-
tective anti-tetanus antibody concentrations 
in approximately 2,000 adults presenting for
wound care in five academic emergency de-
partments. More than 90% of the patients had
anti-tetanus antibody concentrations above the
protective cutoff value of 0.1 IU/mL. Lower
prevalences of protection were found in elderly
patients, those with less education, immigrants
from countries outside North America or West-
ern Europe, and those with an unknown vac-
cination history or known inadequate vaccina-
tion [79].
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prone wounds who have never completed a
primary immunization series. In small chil-
dren, the routine dose of HTIG may be calcu-
lated by the body weight (4 IU/kg). However,
it may be advisable to administer the entire 250
IU regardless of the child’s size, because theo-
retically, the same amount of toxin will be pro-
duced in a child’s as in an adult’s body by the
infecting organism (53,66,76) (Grade B).
If a patient has not completed a primary 
immunization series, a tetanus booster is re-
quired, and the patient will need followup 
to complete the series. If the patient has had
primary immunization, a booster is given if 
the last dose was more than five years pre-
viously with a tetanus-prone wound or more
than ten years previously with a non-tetanus-
prone wound. Patients with a contraindication
to TT must be managed with HTIG alone
[54,67,77,78] (Grade B).
Immunization in high-risk groups. Patients
from certain high-risk groups often present to
the emergency department for care and require
special attention, as standard prophylaxis may
not provide sufficient protection from tetanus.
These groups include elderly patients, human
immunodeficiency virus (HIV)-infected indi-
viduals, and intravenous drug users (IVDUs).
Because of a declining immune system, el-
derly patients do not respond as well to vacci-
nation as do children and younger adults. The
formation of tetanus antibodies after vaccina-
tion is not as rapid as in younger adults, the
peak titer is not as high, and the antibodies do
not last as long [80]. In a similar fashion, the
immunogenic response to vaccination in HIV-
infected individuals is blunted, and antitoxin
antibody concentrations decline more quickly
than in HIV-negative individuals. As expected,
TABLE 4. TETANUS PROPHYLAXIS OF ACUTE WOUNDS
Clean Tetanus-prone
wounds wounds
Primary immunization Td Td HTIG
Not complete Yes Yes Yes
Completed 5 years No No No
Last booster 5 years No Yes No
Last booster 10 years Yes Yes No
Adapted from ACIP [67]. See text for abbreviations.
Given the present low incidence of tetanus
in the U.S. and the relatively high prevalence
of protective tetanus antitoxin in individuals
who are not members of defined risk groups,
questions have arisen regarding the appro-
priateness of the ACIP guidelines for tetanus
prophylaxis in wound care [79]. Neverthe-
less, the current recommendations should be
maintained for several reasons. As reviewed 
by Wassilak and Galazka, individual anti-
body responses and the duration of immunity
after tetanus immunization differ widely [54].
Tetanus occurs when the amount of toxin pro-
duced by wounds contaminated with C. tetani
overwhelms available antitoxin. Periodic re-
ports of tetanus cases occurring in the face 
of protective tetanus antitoxin concentrations
support the concept that no single antibody
titer value can define minimum protection for
all patients. Anti-tetanus antibody concentra-
tions used to define population immunity do
not guarantee individual protection [54].
Tetanus prophylaxis for the acute wound. In the
setting of an acute injury, the CDC recom-
mendations for tetanus prophylaxis depend 
on the wound characteristics and the patient’s
immunization history (Tables 3 and 4) [67].
Many characteristics of wounds encountered in
the emergency department render them non-
tetanus-prone: Recent; linear with sharp edges;
well vascularized; and not obviously contami-
nated or infected. All other wounds are con-
sidered tetanus-prone, particularly those re-
sulting from blunt trauma and bites and those
that are grossly contaminated or infected. The
CDC recommends HTIG 250 IU, given at a site
separate from the TT to avoid interaction be-
tween the two, only for patients with tetanus-
TABLE 3. RISK OF TETANUS ACCORDING TO
WOUND CHARACTERISTICS
Non-tetanus prone Tetanus prone
6 h old 6 h old
1 cm deep 1 cm deep
Clean Contaminated
Linear Stellate
Neurovascular intact Denervated, ischemic
Not infected Infected
Adapted from Edlich et al. [65].
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the response to vaccination deteriorates as HIV
infection progresses [56].
The elderly, HIV-infected, or otherwise im-
munocompromised patient may not have a
protective concentration of tetanus antibodies
at the time of injury, and vaccination alone may
not lead to prompt or sufficient formation of
antibodies to protect the patient. If prophylaxis
is indicated, more liberal use of HTIG may 
be warranted in these patients, regardless of
primary immunization, to ensure protection
against tetanus. More frequent dosing of TT
may help sustain antibody concentrations in
the protective range. There are no official
guidelines endorsing this approach. However,
in considering the risks and benefits to a given
patient, it should be kept in mind that HTIG
and TT are safe, whereas the morbidity and
mortality associated with acute tetanus are con-
siderable [81] (Grade E).
Intravenous drug users are a burgeoning
group at high risk for tetanus. They accounted
for 18% of all cases of tetanus between 1995 and
1997 but only 2.1–4.5% of the cases seen be-
tween 1982 and 1994 [56]. Factors that place 
IVDUs at risk include low rates of immuniza-
tion, contaminated drugs, repeated injection
wounds under dirty conditions, and formation
of skin abscesses and chronic ulcers, which pro-
vide ideal conditions for tetanus development
[56]. Social and behavioral factors often lead to
delayed or sporadic medical care, which com-
pound these risk factors. Intravenous drug
users may present for complaints unrelated to
acute wounds. However, their drug use should
be considered a risk factor that requires atten-
tion to tetanus prophylaxis [56,81] (Grade E).
Post-splenectomy vaccination
The spleen was once viewed as a superflu-
ous organ, similar to the appendix, and it was
removed with impunity if injured. It was not
until the 19th Century that the spleen was as-
sociated with immune function. The earliest as-
sociation linking splenectomy to life-threaten-
ing infection was reported by Morris and
Bullock in 1919, when they demonstrated a
four-fold increase in lethal infection with Bac-
terium enteritidis in splenectomized rats [82].
Subsequently, King and Schumacker reported
five cases of severe infection in infants follow-
ing splenectomy for spherocytosis [83]. Subse-
quent reports confirmed these observations,
and the term “overwhelming post-splenec-
tomy infection” (OPSI) was popularized by Di-
amond in 1969 [84].
The surgical management of splenic injuries
has evolved over the past several decades, re-
sulting from sound scientific evaluation. Al-
though the infectious consequences of splenec-
tomy are well known, preventive practices
differ substantially among surgeons. Few writ-
ten guidelines delineate evidence-based rec-
ommendations for vaccination, and what infor-
mation is available is not well disseminated [4].
Splenic function. Because of its unique archi-
tecture and abundant blood flow, the spleen
plays a prominent role in the defense against
blood-borne organisms. Ninety percent of ar-
terial blood flow to the spleen is directed
through the red pulp and circulates in the
meshwork of splenic cords before squeezing
through the endothelial pores of the splenic si-
nuses [85]. Because of the organization of the
microcirculation, blood-borne bacteria remain
in contact with splenic phagocytes, allowing
clearance of even poorly opsonized bacteria.
Invasive, encapsulated bacterial pathogens
possess a surface polysaccharide capsule that
impedes opsonization by Ig or complement in
the circulation. The spleen plays an important
role in the production of immune mediators
that aid in the clearance of bacteria and viruses.
The mediators, known as opsonins, coat circu-
lating bacteria and viruses and convert them
into immune complexes. Although the liver
clears some of these circulating immune com-
plexes, the spleen is predominant [85].
Several lines of evidence suggest that
splenectomized patients have compromised
humoral immunity, deficient in both comple-
ment and Ig. A particular subset of circulating
memory B cells (IgM memory B cells, which re-
spond to bacterial polysaccharides; 86), are 
absent in congenitally asplenic patients and are
severely depleted immediately after splenec-
tomy. Memory B cells are highly specific, long-
lived cells generated in germinal centers after
somatic mutation, selection, and class switch,
in response to a specific etiologic agent or
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vaccine. They persist and produce antibodies
rapidly on a second challenge with the same
antigen. In humans, 30–60% of B cells are con-
sidered memory B cells, one-half of which are
IgM memory B cells. The IgM memory cells are
dependent on a functional spleen for their gen-
eration and survival and are responsible for the
T-cell-independent response to bacterial poly-
saccharides [87].
The spleen produces tuftsin, a tetrapeptide
(Thr-Lys-Pro-Arg) that stimulates phagocyto-
sis. Tuftsin is part of the specific carrier mole-
cule leukokinin, which is cleaved following
passage through the spleen, leaving a molecule
known as leukokinin-S. Tuftsin binds to spe-
cific receptors on granulocytes, monocytes,
macrophages, and natural killer cells. Once ac-
tivated, tuftsin modulates the biological activ-
ities of phagocytic cells [88]. The amount of
tuftsin is significantly lower after splenectomy
[89]. Szendroi et al. demonstrated a return to
normal tuftsin concentrations in children after
splenectomy for trauma following autotrans-
plantation of minced splenic tissue into the
omentum [90].
The spleen produces properdin, an opsonin
that plays a crucial role in the alternative path-
way of complement activation. The alternative
pathway is activated in the absence of anti-
body, and generates both soluble and mem-
brane-bound forms of C3 convertase, an en-
zyme that catalyzes the proteolysis of C3. The
alternative pathway form of C3 convertase de-
cays rapidly unless it is stabilized by binding
with properdin. Binding of properdin with C3
convertase allows conversion of C3 to C3b.
Post-splenectomy patients lack properdin,
which may contribute to the risk of developing
OPSI [91].
An exclusive function of the spleen, pitting,
is clearance of intraerythrocyte inclusions,
while maintaining the integrity of the red blood
cell. The inclusions removed by the spleen in-
clude particulate matter, Heinz bodies (dena-
tured hemoglobin), Howell-Jolly bodies (nu-
clear remnants), and Pappenheimer bodies
(iron granules) [91]. Red blood cells must de-
form to pass through slit-like fenestrations of
the sinus endothelium. Rigid inclusions, unable
to traverse the narrow passage, are entrapped,
excluded from the cell, and phagocytized by
resident macrophages. Asplenic and hyper-
splenic patients lose their ability to clear dam-
aged red blood cells and inclusions from the
circulation. These patients display a variety of
abnormal erythrocytes in peripheral blood
smears [91].
The spleen acts as a reservoir for platelets
and granulocytes. In non-pathologic states, the
spleen sequesters approximately 30% of the
body’s platelets, and can release them into the
circulation in response to certain stimuli. In hy-
persplenism secondary to portal hypertension,
the spleen can sequester as many as 90% of
platelets, resulting in severe thrombocytope-
nia. In contrast, there is a significant increase
in circulating platelet and granulocyte counts
after splenectomy. These counts usually nor-
malize within a few days [91].
Overwhelming post-splenectomy infection. Over-
whelming post-splenectomy infection is a ful-
minant, potentially life-threatening condition
that may occur weeks to years after removal of
the spleen. The precise incidence of OPSI re-
mains controversial; published estimates differ
considerably for many reasons, including dif-
ferent disease definitions, duration of followup,
stratification for age, indication for splenec-
tomy, and underlying disease [92].
The risk of post-splenectomy sepsis is high-
est in children, especially those under two
years of age. There are, however, reported
cases 20 to 40 years after splenectomy [93]. A
collective critical review of the literature on
OPSI from 1952 to 1987 showed that the inci-
dence in children under 16 years of age was
4.4% with a mortality rate of 2.2%. The corre-
sponding figures for adults were 0.9% and
0.8%. The incidence of sepsis after splenectomy
caused by trauma was 15.7% in infants and
10.4% in children younger than 5 years [94].
Splenectomy performed for a hematologic
disorder such as thalassemia, hereditary sphe-
rocytosis, or lymphoma carries a higher risk
than splenectomy performed as a result of
trauma. One recent study calculated the risk of
sepsis as 0.73 per 1,000 person-years after
splenectomy for hereditary spherocytosis [95].
Several studies reported the risk for patients
with thalassemia to range from 11–25% [94,96].
Patients with Hodgkin disease, particularly
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those who received chemotherapy, are at the
greatest risk (25–33%) [94,96].
A potential contributor to the lower rate of
infection after splenectomy for trauma is the
frequent existence of splenic implants or ac-
cessory spleens [97]. Small implants of splenic
tissue (splenosis) are found in the peritoneum
of 50% of patients who undergo splenectomy
for trauma. About 10% of such patients may
also have accessory spleens [98]. Unfortu-
nately, the degree of protection offered by
splenosis or accessory spleens is both variable
and unpredictable. A number of cases of OPSI
have been reported in the presence of residual
splenic tissue or splenic implants [99].
Unfortunately, most of the published data on
OPSI occurrence antedate the widespread avail-
ability of the pneumococcal and Haemophilus in-
fluenzae vaccines, so the current incidence may
be lower. For example, a Danish study found
that the incidence of pneumococcal infection in
splenectomized children decreased dramati-
cally following the introduction of the pneu-
mococcal vaccine and the promotion of early
penicillin therapy for febrile episodes [100].
One of the most reliable reports relating to
the incidence of OPSI is that of Schwartz et al.,
who applied actuarial methods to a population
free of selection bias that had consistent long-
term followup. The risk of OPSI was estimated
to be in the range of one case per 500 person-
years of observation. However, the cumulative
risk of infection severe enough to necessitate
hospitalization was 33% by the end of 10 years
[101].
The time since splenectomy is also an im-
portant risk factor. Several studies have shown
that 50–70% of admissions to the hospital 
for serious infections occur within the first 
two years. In splenectomized young children,
80% of OPSI cases occur within this time
[98,102,103]. However, some degree of risk per-
sists indefinitely. Thirty-three percent of post-
splenectomy pneumococcal infections and 42%
of OPSI occurred more than five years post-
splenectomy [104]. There also are individual
cases of OPSI reported more than 40 years af-
ter splenectomy [92].
Most serious infections after splenectomy are
caused by encapsulated bacteria. Pneumococ-
cal infections account for approximately 50–
90% of reported cases, with a mortality rate 
as high as 60%. Haemophilus influenzae type b,
Neisseria meningitidis, and Group A Streptococ-
cus account for an additional 25% of infections.
Haemophilus infections are particularly impor-
tant in children [92]. Other rarely implicated or-
ganisms are Capnocytophaga canimorsus (for-
mally called DS-2), which can cause fulminant
sepsis after dog bites. Others are group B strep-
tococci, Enterococcus spp., Bacteroides spp., and
Pseudomonas aeruginosa. Bacterial proliferation
in OPSI may be so extreme that bacteria are
noted in buffy coat preparations, extracellu-
larly, or within neutrophils in a smear made
from unspun peripheral blood [105].
The splenectomized host is also more suscep-
tible to infections with intraerythrocytic organ-
isms. Protozoal infections following tick bites
(babesiosis) have been responsible for a fulmi-
nant hemolytic febrile state in asplenic individ-
uals. Fatal falciparum malaria has been noted
more frequently in asplenic hosts [103,106].
Overwhelming post-splenectomy infection is
also known as post-splenectomy sepsis syn-
drome or post-splenectomy overwhelming sep-
sis [93,104]. Although meningitis or pneumonia
will accompany OPSI in approximately 50% of
cases, in many adults, there is no obvious source
of infection, and a cryptic source originating in
the nasopharynx is postulated. In children
younger than five years, focal infections are
more common, particularly meningitis [92].
The prodrome of OPSI may be mild and
nonspecific with flu-like symptoms of fever,
malaise, myalgia, headache, vomiting, diar-
rhea, or abdominal pain. Gastrointestinal
symptoms should never distract the physician
from entertaining the diagnosis of OPSI. Many
patients have had true rigors for a day or two
before receiving definitive medical manage-
ment [107]. Prodromal symptoms may be fol-
lowed by rapid evolution to bacteremia and
septic shock accompanied by hypotension,
anuria, and clinical evidence of disseminated
intravascular coagulation, making this syn-
drome a true medical emergency. Severe hy-
poglycemia may also be present. The subse-
quent clinical course often mirrors that of the
Waterhouse-Friderichsen syndrome with bilat-
eral adrenal hemorrhages noted at autopsy
[92]. Extremity gangrene necessitating ampu-
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tation has been reported in survivors sec-
ondary to the combination of hypotension and
disseminated intravascular coagulation [107].
Despite appropriate antibiotics and intensive
therapeutic intervention, the overall mortality
rate in older published studies of established
cases of OPSI ranged from 50–70% [107,108].
More recent information suggests that when
informed patients seek medical attention
promptly, their mortality rate may be reduced
to approximately 10%. Of patients who die,
more than 80% do so within the first 48 hours
of hospital admission, illustrating the impor-
tance of early diagnosis and therapy. Among
survivors, other sequelae, in addition to gan-
grene and amputation, include deafness asso-
ciated with either meningitis or mastoid os-
teomyelitis and aortic insufficiency secondary
to endocarditis [92,109].
Vaccines. The first pneumococcal polysaccha-
ride vaccine was released in the 1940s, but was
withdrawn from the market when penicillin
and sulfonamide drugs became widely avail-
able, primarily on the assumption that pneu-
mococcal disease would be eradicated by an-
tibiotics. When this proved to be untrue, and
the morbidity and mortality of pneumococcal
disease once again were recognized, pneumo-
coccal vaccines were re-licensed in the U.S. in
1977, when a 14-valent polysaccharide vaccine
was released, to be replaced by a 23-valent vac-
cine in 1980. In February 2000, a 7-valent pro-
tein conjugate pneumococcal vaccine was li-
censed for pediatric use in the U.S. [110].
At least 90 serotypes of Streptococcus pneu-
moniae are known. The most important viru-
lence factor of the bacterium appears to be the
polysaccharide capsule that facilitates evasion
of host defenses, as opsonization and phago-
cytosis of the organism leading to a humoral
immune response yields clearance and eradi-
cation. Current vaccines are based on stimu-
lating immunity to capsular polysaccharide
antigen [110].
Three pneumococcal polysaccharide vac-
cines are licensed and marketed in the U.S.,
namely Pneumovax 23 (Merck, West Point,
PA), Pnu-Immune 23 (Wyeth Laboratories,
Madison, NJ) and Prevnar, a 7-valent protein
conjugate vaccine (Wyeth). The first two vac-
cines contain 25 mcg of capsular polysaccha-
ride from each of 23 serotypes (1, 2, 3, 4, 5, 6B,
7F, 8 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C,
19F, 19A, 20, 22F, 23F, 33F), which collectively
account for 85–90% of invasive pneumococcal
disease in adults in the U.S. Serotypes 4, 6B, 9V,
14, 18C, and 23F account for 80% of invasive
infections among U.S. children. The six pneu-
mococcal serotypes that most frequently cause
invasive drug-resistant disease in the U.S. (6B,
9V, 14, 19A, 19F, 23F) are included in the vac-
cines [110,111].
The limitations of the current pneumococcal
polysaccharide vaccines have driven efforts to
develop the next generation of pneumococcal
vaccines, in particular, protein conjugates.
Serotype-specific antibody concentrations de-
cline substantially after 5 to 10 years [112]. In
addition, current pneumococcal vaccines are T-
cell-independent immunogens, and therefore
do not induce T-cell-dependent responses (i.e.,
no immunologic memory is induced). Further-
more, the vaccine is not immunogenic, and
hence is not effective, in children under the age
of two years, who suffer the highest rates of
morbidity and mortality from invasive pneu-
mococcal infections [110].
In 2000, the 7-valent conjugated pneumococ-
cal vaccine (Prevnar) was approved by the
Food and Drug Administration. This vaccine
contains a solution of the capsular antigens of
serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, each
individually conjugated to a non-toxic variant
of diphtheria toxin, namely CRM 197 protein.
Conjugation of a polysaccharide to a protein
changes the nature of the anti-polysaccharide
antibody response from a T-cell-independent
to a T-cell-dependent type. This induces T
helper cells to stimulate polysaccharide-spe-
cific B cells to mature into antibody-producing
plasma cells or memory cells independent of
splenic function [113].
Concerns about efficacy surround the use of
pneumococcal vaccine. These concerns first
surfaced after the results of a national Veterans
Administration cooperative trial demonstrated
lack of efficacy in preventing pneumococcal
pneumonia [114]. Although this study influ-
enced physicians’ perceptions of the vaccine,
the results were not statistically significant ow-
ing to a type II error in the study design [110].
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Other clinical studies have likewise failed to
demonstrate efficacy in preventing pneumo-
coccal pneumonia in high-risk, elderly persons
[115,116], but each of these trials had serious
methodologic flaws (inadequate sample sizes,
type II errors), problems with disease defini-
tion or diagnosis, or problems with unusual
subject cohorts [116]. In contrast, studies of
South African gold miners, New Guinea high-
landers, and younger persons at high risk of
pneumococcal infection but otherwise im-
munologically intact have demonstrated effi-
cacy [117,118]. Similarly, studies published in
the last 20 years have demonstrated vaccine ef-
fectiveness rates of 40–100% in preventing in-
vasive pneumococcal disease in adult, includ-
ing elderly, patients [119,120].
A review of published pediatric trials demon-
strated that conjugate pneumococcal vaccines,
when administered in a three-dose series at 2, 4,
and 6 months of age, are safe and more im-
munogenic than the polysaccharide vaccines
[121]. A trial in U.S. infants using a seven-
serotype conjugate vaccine induced high titers
of type-specific antibody to all serotypes in-
cluded in the vaccine, which included 78% of
the serotypes responsible for invasive disease in
children less than two years of age in the U.S.,
and induced immunologic memory to a booster
dose of polysaccharide vaccine [122].
Although safe and effective, pneumococcal
polysaccharide vaccine does have side effects.
For example, as many as 50% of recipients ex-
perience mild, self-limited local effects after the
first dose. Fortunately, moderate to severe local
or systemic reactions are rare. A review of nine
randomized controlled clinical trials of pneu-
mococcal vaccine revealed local reactions in
fewer than one-third of recipients, and no re-
ports of severe febrile or anaphylactic reactions
[123]. Early studies reported a higher than ex-
pected frequency and severity of systemic and
local reactions in persons receiving a second
dose of vaccine in a 2–4-year period [124]. Sub-
sequently, it was determined that re-immuniza-
tion of otherwise immunocompetent persons at
least five years after the first dose was not asso-
ciated with a higher risk of adverse events or
hospitalization [125]. Published data demon-
strate the safety of the pneumococcal conjugate
vaccine in infants, children, and adults [126].
Invasive H. influenzae disease is caused by
one of six serotypes, designated “A” to “f”. Be-
fore the introduction of vaccines for H. influen-
zae, approximately one in 200 children devel-
oped invasive disease before the age of five
years, with a mortality rate of 4%. By 2000, H.
influenzae type B invasive disease reported to
the CDC among children under the age of 
five years had declined by 96%, from 41 cases
per 100,000 in 1987, to 1.6 cases per 100,000 in
2000 [127]. Ninety-five percent of the cases of
invasive H. influenzae disease among children
younger than 5 years were caused by organ-
isms of serotype B [128].
The first H. influenzae vaccine, introduced 
in 1985, contained purified polyribosyl-ribitol
phosphate (PRP), a high molecular weight
polymer prepared from type b strains. By 1989,
the vaccine was conjugated, thereby conferring
T-cell-dependent characteristics that substan-
tially increased the immune response. Cur-
rently, the approved H. influenzae vaccines are
conjugated to TT (PRP-T), diphtheria toxoid
(PRP-D), modified diphtheria toxoid (HbOC),
or external antigens of Neisseria meningitidis
outer membrane protein (PRP-OMT). ActHIB®
(Haemophilus influenzae B Conjugate Vaccine;
Aventis Pasteur), is a polysaccharide–protein
conjugate vaccine, with each dose of 0.5 mL for-
mulated to contain 10 mcg of purified capsular
polysaccharide conjugated to 24 mcg of inacti-
vated TT [129,130].
The immunogenicity of ActHIB has been
demonstrated in worldwide studies. On aver-
age, ActHIB induced anti-PRP concentrations
1.0 mcg/mL in 90% of infants after the pri-
mary series and in more than 98% of infants af-
ter a booster dose [131].
The conjugate vaccine is immunogenic in
children with sickle cell anemia, a condition
that may increase susceptibility to Haemophilus
serotype B disease. Two doses of ActHIB given
at two-month intervals induced anti-PRP anti-
body titers of at least 1.0 mcg/mL in 89% of
these children with a mean age of 11 months.
This is comparable to the anti-PRP antibody
titers demonstrated in normal children of sim-
ilar age following two doses of ActHIB [132].
More than 7,000 infants and children two
years of age or younger received at least one
dose of ActHIB during U.S. clinical trials. Of
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these, 1,064 subjects 12–24 months of age who
received ActHIB alone had no serious or life-
threatening adverse reactions. Adverse reac-
tions commonly associated with a first ActHIB
immunization of children 12–15 months of age,
who previously had not been immunized with
any Haemophilus conjugate vaccine, included
local pain, redness, and swelling at the injec-
tion site (2–10%). Systemic reactions included
fever, irritability, and lethargy (1–12%) [128].
Neisseria meningitidis is classified into 13
serogroups on the basis of the antigenic prop-
erties of the capsular polysaccharide. Sero-
groups A, B, and C account for more than 90%
of disease worldwide. Serogroups A and C pre-
dominate throughout Asia and Africa, whereas
serogroups B and C are responsible for the ma-
jority of disease in Europe and the Americas.
In the U.S., 45% of meningococcal infections are
caused by serogroup C, and as many as 40% of
infections are caused by serogroup B. In addi-
tion, in several countries, including the U.S., the
proportion of disease attributable to serogroup
Y has increased over the past decade [133].
Unlike the serogroup A and C polysaccha-
ride antigens, serogroup B antigen is poorly im-
munogenic in humans. Even after a natural
infection with a serogroup B meningococcus,
antibodies against capsular polysaccharide
antigen consist primarily (more than 95%) of
IgM, with low avidity and poor bactericidal ac-
tivity with human complement. The poor anti-
genicity of the serogroup B polysaccharide
likely is explained by its structural identity to
a glycoprotein found on human tissues, the
fundamental role of which is to modulate the
migration of neural tissues. Naturally occur-
ring anti-B polysaccharide antibodies are pre-
sent in 80% to 90% of healthy adults and in cord
sera of apparently healthy full-term babies
[134]. These naturally occurring antibodies
usually have low avidity. However, anti-B
monoclonal antibodies bind to human embry-
onic neural tissue in vitro [135], although no
adverse effects have been associated with the
presence of either natural or vaccine anti-B cap-
sular polysaccharide antibody. However, over-
coming the apparent immune tolerance to this
self-antigen carries the theoretical risk of in-
ducing autoimmunity and interfering with nor-
mal cell migration [136].
The only meningococcal vaccine currently
available in the U.S. (Menomune; Aventis Pas-
teur) contains polysaccharide serogroups A, C,
Y, and W-135. The vaccine therefore does not
protect against serogroup B. Each 0.5-mL dose
is formulated to contain 50 mcg of purified cap-
sular antigen from each of the serogroups.
The immunogenicity and clinical efficacy of
the meningococcal vaccines has been estab-
lished in children and adults. A study per-
formed using four lots of Menomune in 150
adults showed at least a four-fold increase in
antibodies to all serogroups in more than 90%
of the subjects [137]. A study conducted in 73
children ages 2–12 years revealed seroconver-
sion rates, measured by a two-fold rise in anti-
body titers in a solid-phase radioimmunoassay,
to be 99% for group A, 99% for group C, 97%
for group Y, and 89% for group W-135 [138].
Adverse reactions to meningococcal vaccine
are mild and consist primarily of pain and red-
ness at the injection site for one or two days.
Pain at the site of injection is the most com-
monly reported adverse reaction; transient
fever developed in fewer than 2% of young
children. Adverse events reported in adults in-
clude pain and tenderness at the injection site,
occurring in 2–10% of recipients, and headache,
malaise, fever, and chills, occurring in 1–12%.
On rare occasion, IgA nephropathy has fol-
lowed vaccination with Menomune; however,
a causal relation has not been established
[137,138].
Evidence-based recommendations. The organ-
isms responsible for OPSI for which vaccines
are available are S. pneumoniae, N. meningiditis,
and H. influenzae type B. There are few con-
trolled trials evaluating the use of vaccines in
the prevention of OPSI, but two modern re-
ports add substantial evidence in favor of post-
splenectomy vaccination. Utilizing the Danish
National Patient Registry, all children up to 15
years of age who underwent splenectomy dur-
ing the period 1979 to 1987, and all children of
the same age group who were admitted to a
hospital during the same period because of S.
pneumoniae meningitis or bacteremia, were
studied [100]. A similar Danish study covering
the period 1969 to 1978, when pneumococcal
vaccine was not available, was used as a con-
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trol. During the pre-vaccine period, 4% of
splenectomized children developed invasive
pneumococcal infection, in contrast to none of
the children vaccinated during the period 1979
to 1987. Since 1982, antibiotic treatment of
splenectomized children having a fever has
been recommended in Denmark. The program
of pneumococcal vaccination and defined an-
tibiotic prophylaxis has been highly efficacious
in preventing post-splenectomy infection in
children [100]. The second report was a series
of more than 200 asplenic adult hematology pa-
tients who had been immunized with pneu-
mococcal vaccine, in whom only four episodes
of pneumococcal sepsis were reported in 13
years. Notably, all four of these episodes in-
volved an infecting serotype that was not cov-
ered by the vaccine, lending indirect support
to the efficacy of the pneumococcal vaccine
even in immunocompromised patients [139].
The ACIP recommends the use of the 23-va-
lent polysaccharide pneumococcal vaccine for
persons 2 to 64 years of age who have func-
tional or anatomic asplenia [140] (Grade D). Be-
cause the true incidence of OPSI is unknown,
the efficacy of vaccination cannot be ascer-
tained precisely. Although some cases of OPSI
have resulted from uncommon serotypes not
included in the vaccine, a large percentage of
post-splenectomy patients with serious pneu-
mococcal infections were never vaccinated
[141], which suggests that pneumococcal dis-
ease is likely prevented in most vaccinated pa-
tients. True vaccine failures are uncommon
[142].
The ActHIB conjugate vaccine has been in
widespread use for infant immunizations in 
the U.S. and Europe, and has reduced H. in-
fluenzae type B disease transmission, as well as
the risk to non-immunized individuals [143].
The protective concentration of HIB antibody
is not known, although previous studies have
shown that as many as 96% of adults have titers
above the presumed protective concentration
(1 mcg/mL) [144]. Therefore, some countries
do not recommend H. influenzae type B vacci-
nation of people older than 15 years [145].
Overall, because of naturally occurring anti-
body, vaccination of the general population is
not recommended. However, because ActHIB
vaccine is free of any serious side effects, and
because splenectomized individuals are more
susceptible to lethal sepsis than the general
population, 8–10% of which is attributable to
H. influenzae type B, these high-risk individu-
als should be considered for ActHIB conjugate
vaccine [146] (Grade D).
The available meningococcal vaccine pro-
tects against serotypes A, C, Y, and W-135 of
N. meningiditis, an important cause of bacterial
meningitis and sepsis in children and young
adults in the U.S. [147]. However, vaccination
will not eliminate the risk because the vaccine
does not protect against serotype B and because
protection against serogroups C and Y is only
partial [147]. Nevertheless, those at risk for the
disease (including asplenic patients) should be
vaccinated (Grade D).
Timing. Patients undergoing elective splenec-
tomy should be vaccinated at least two weeks
preoperatively to maximize the antibody re-
sponse against T-cell-independent immuno-
gens. Giebink et al. demonstrated that antibody
titers were 50% lower when patients were vac-
cinated after splenectomy than when they were
vaccinated at least two weeks preoperatively
[148] (Grade C).
The timing of immunization after emer-
gency splenectomy for trauma is debated, with
conflicting data supporting a variety of rec-
ommendations [4]. Part of the problem has
stemmed from studies using antibody assays,
which may be misleading. Barringer et al. stud-
ied the effect of anesthesia and splenectomy on
the antibody response to pneumococcal vacci-
nation [149]. Measuring the antibody response
by radioimmunoassay showed no significant
difference between groups immunized pre-
operatively, immediately postoperatively, or
three weeks later. Similarly, Caplan et al. stud-
ied 16 patients undergoing splenectomy for
trauma and, by enzyme-linked immunosorbent
assay (ELISA), measured the antibody response
to 12 antigens in the patients and control sub-
jects [150]. The rates of response and the geo-
metric mean increase in the titer in the groups
were not different. The authors therefore sug-
gested that the vaccine could be administered
in the immediate postoperative period.
Conversely, extensive studies in Denmark
led to the establishment in 1991 of national
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guidelines for vaccination and revaccination of
splenectomized children and adults [151]. The
Danish guidelines recommend that patients
undergoing urgent or otherwise unplanned
splenectomy be immunized no less than 14
days postoperatively.
Waiting two weeks before vaccinating car-
ries the risk of forgetting to vaccinate, but solid
data suggest that the antibody response is sub-
optimal when patients are vaccinated less than
14 days post-splenectomy. Shatz et al. showed
that although geometric mean antibody con-
centrations measured by ELISA were similar
among trauma patients immunized at post-
splenectomy day 1, 7, or 14, functional anti-
body titers, measured by opsonophagocytosis
assay, were significantly higher in the 14-day
group [152]. This assay measures only func-
tional antibody and eliminates non-protective
antibodies that may cross-react against the cap-
sule or antigen, which can be falsely elevated
when measured by radioimmunoassay and
ELISA [153]. Therefore, there is likely a higher
correlation between opsonophagocytic anti-
body titers and pneumococcal vaccine efficacy
than between IgG antibody concentrations
measured by ELISA and efficacy [154]. Delay-
ing vaccination beyond 14 days did not appear
to improve the immune response. In another
study by Shatz et al., antibody titers were not
significantly different in splenectomized trauma
patients vaccinated at 14 vs. 28 days postoper-
atively [155]. Therefore, patients undergoing
emergency splenectomy should receive immu-
nizations 14 days later (Grade D).
Revaccination. Antibody persistence after vac-
cination, and the presence of an anamnestic
response with reintroduction of a specific anti-
gen, dictate the need for and timing of revac-
cination. The antigens in commercial vaccines
induce the production of serotype-specific an-
tibodies. Higher titers develop within two to
three weeks in most healthy adults, with a
comparable response occurring in anatomic or
functionally asplenic patients of the same age.
Because polysaccharide antigens alone do not
illicit a T cell response, and therefore provide
no immunologic memory, future responses to
the specific antigen depend on the circulating
antibody concentrations present at the time of
re-exposure. Therefore, the need for revaccina-
tion of splenectomized patients is dependent
on the persistence of the antibody [4].
Mufson et al. demonstrated that five years
after immunization, in healthy adult subjects,
the titers of type-specific pneumococcal anti-
bodies to serotypes 1, 3, 4, 8, 12F, 14, and 23F
were 90% of those obtained one month after
vaccination [156]. At 10 years, antibody con-
centrations measured by radioimmunoassay
remained elevated only for serotypes 4 and 8,
and were not significantly different from pre-
vaccination levels for the other capsular anti-
gens tested. Other studies have demonstrated
similar patterns in antibody retention lasting at
least 3 to 4 years, with a subsequent decline that
was more pronounced in splenectomized chil-
dren [157].
The literature demonstrates a variety of re-
vaccination practices. However, the CDC sug-
gests a single booster dose for those older than
two years of age who are at high risk for seri-
ous pneumococcal infection and those most
likely to have a rapid decline in antibody titers,
which includes those with either functional 
or anatomic asplenia. A single revaccination
should be given at least five years after the first
dose, with further dosing not recommended
routinely (Grade D). There currently is no rec-
ommendation to revaccinate for H. influenzae
type b or meningococcus [140].
Children younger than five years. The 7-valent
pneumococcal conjugate vaccine is recom-
mended for all children 24–59 months of age
who are at high risk for invasive pneumococ-
cal infection. High-risk children include those
with sickle cell disease or other types of func-
tional or anatomic asplenia [158]. For high-risk
children 24–59 months of age who have not re-
ceived either the 23-valent pneumococcal poly-
saccharide vaccine or the PCV7, two doses of
PCV7 should be given at an interval of six to
eight weeks, followed by a single dose of the
23-valent vaccine no less than six to eight weeks
after the last dose of PCV7. An additional dose
of the 23-valent vaccine is recommended three
to five years after the last dose [158] (Grade D).
Current immunogenicity data suggest that
PCV7 induces a primary immune response that
will provide immune memory for boosting an-
SURGICAL INFECTION SOCIETY GUIDELINES FOR VACCINATION 299
tibody responses to some serotypes when the
23-valent vaccine is given. Because this vaccine
provides substantially expanded serotype cov-
erage, its use is recommended for high-risk
children [158]. This age group should also re-
ceive vaccination against meningococcus and
H. influenzae type b [128,138] (Grade D).
Antibiotic prophylaxis is recommended for
all children with sickle cell disease and func-
tional or anatomic asplenia, regardless of
whether they have received pneumococcal im-
munizations (Grade B). Oral administration of
penicillin V potassium is recommended at a
dose of 125 mg twice a day until three years of
age and 250 mg twice a day thereafter. Chil-
dren who have not been vaccinated appropri-
ately and who have had an invasive pneumo-
coccal infection may discontinue penicillin
prophylaxis after five years of age [158].
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